Recombinant Human WT1 Protein，His

WT1 (Wilms' Tumor 1) is a transcription factor that plays a crucial role in kidney and gonadal development, and its mutation or aberrant expression is associated with various cancers, particularly Wilms' tumor and leukemia. Research on WT1 recombinant protein has gained momentum due to its potential as a diagnostic marker and therapeutic target in cancer treatment. The WT1 protein is notably involved in regulating cell growth and differentiation, which directly links it to tumorigenesis. Studies have shown that WT1 is overexpressed in many types of tumors, making it a promising candidate for immunotherapy. The generation of WT1 recombinant proteins facilitates the investigation of its biological functions, interactions with other cellular pathways, and mechanisms of action. Advances in recombinant DNA technology have enabled the production of WT1 protein in sufficient quantities, allowing for detailed structural and functional analyses. By creating WT1-based vaccines or targeted therapies, researchers aim to harness the immune system to recognize and eliminate cancer cells expressing this protein. Furthermore, the study of WT1 recombinant protein has important implications for understanding the underlying biological mechanisms of tumor development and progression, as well as the potential for developing novel therapeutic approaches. Overall, WT1 recombinant protein research represents a significant intersection of developmental biology, oncology, and immunology, with the hope of translating these findings into effective clinical applications for cancer treatment.